Literature DB >> 10806182

Bacteriology of infected cavitating lung tumor.

W Y Liao1, Y S Liaw, H C Wang, K Y Chen, K T Luh, P C Yang.   

Abstract

Differentiation between in situ infection and simple tumor necrosis in cavitating lung tumors by means of imaging studies is difficult. In this study, we prospectively investigated the role of ultrasound (US)-guided transthoracic aspiration for bacteriologic examination of infected cavitating lung tumors, and the influence of the culture results on the treatment of patients. Twenty-two patients (18 men and four women) with cavitating lung tumors treated from January 1996 to October 1998 were included. All patients underwent US-guided transthoracic aspiration for bacterial, fungal, and mycobacterial cultures. Microorganisms were isolated from six of seven febrile patients and one of 15 nonfebrile patients. A total of nine pathogens were isolated from seven patients: Klebsiella pneumoniae (n = 3); Haemophilus influenzae (n = 2); Enterococcus faecium (n = 1); Bifidobacterium (n = 1); Shewanella putrefaciens (n = 1); and Mycobacterium tuberculosis (n = 1). Two pathogens were isolated from the aspirate cultures in two patients, while the others had monomicrobial infection. The six febrile patients who had positive lung aspirate cultures were treated with empiric antimicrobial agents before the culture results were available, and the culture results led to adjustment of the antibiotic regimen in five of these. The clinical conditions of the six patients with infected cavitating lung tumors improved after the initiation of individualized antimicrobial treatment. Pneumothorax occurred in one patient, and was the sole procedure-related complication. In conclusion, US-guided transthoracic aspiration is helpful for differentiating infected cavitating lung tumors from simple tumor necrosis. Infection in cavitating lung tumors is common among febrile patients, and the culture results can guide modification of the antimicrobial therapy.

Entities:  

Mesh:

Year:  2000        PMID: 10806182     DOI: 10.1164/ajrccm.161.5.9905103

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  7 in total

Review 1.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 2.  Human infection with Shewanella putrefaciens and S. algae: report of 16 cases in Martinique and review of the literature.

Authors:  Nicolas Vignier; Morgane Barreau; Claude Olive; Emilie Baubion; Rafaelle Théodose; Patrick Hochedez; André Cabié
Journal:  Am J Trop Med Hyg       Date:  2013-05-20       Impact factor: 2.345

3.  Postobstructive Pneumonia: An Underdescribed Syndrome.

Authors:  Michael S Abers; Barcleigh P Sandvall; Rahul Sampath; Carlo Zuno; Natalie Uy; Victor L Yu; Charles E Stager; Daniel M Musher
Journal:  Clin Infect Dis       Date:  2016-02-21       Impact factor: 9.079

Review 4.  Post-Obstructive Pneumonia in Patients with Cancer: A Review.

Authors:  Kenneth V I Rolston; Lior Nesher
Journal:  Infect Dis Ther       Date:  2018-02-01

5.  Rare Shewanella spp. associated with pulmonary and bloodstream infections of cancer patients, China: a case report.

Authors:  Furong Zhang; Yujie Fang; Feng Pang; Shengnan Liang; Xin Lu; Biao Kan; Jianguo Xu; Jinxing Zhao; Yinju Du; Duochun Wang
Journal:  BMC Infect Dis       Date:  2018-09-05       Impact factor: 3.090

6.  Peribronchial Connective Tissue Infection Caused by Bifidobacterium longum and Veillonella Species Mimicking Lung Cancer.

Authors:  Yasuo Takiguchi; Masaru Nagayosi; Yukiko Matsuura; Yoko Akiba; Akira Naito
Journal:  Intern Med       Date:  2020-09-19       Impact factor: 1.271

Review 7.  Immunomodulatory effects of intestinal lung axis microecology and other factors on the prognosis of advanced non-small cell lung cancer.

Authors:  Changxing Shen; Yanbei Ren; Xu Zhang; Qing Xia; Ming Li; Changhui Wang; Lihong Fan
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.